Thus, NLRC5-SA can be used to overcome the size constraint of full-length NLRC5 for delivery to MHC-I defective tumors via viral vectors to induce tumor immunogenicity and to identify tumor antigenic peptides for immunotherapy applications. This evidence concerns the gene NLRC5 and neoplasm.